| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
2,080,000 |
| Market
Cap: |
1.49(M) |
| Last
Volume: |
1,523,296 |
Avg
Vol: |
1,519,138 |
| 52
Week Range: |
$0.714 - $0.714 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sonoma Pharmaceuticals is a global healthcare provider for developing and producing stabilized hypochlorous acid products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. Co.'s products include: Celacyn® Scar Management Gel, which provides scar management by protecting and moisturizing wound and scar sites; Microcyn® Wound Care Management, which provides improved healing properties; Acuicyn™ Eyelid and Eyelash Hygiene, which provides eyelid and eyelash hygiene; and Microdacyn60® Oral Care, which supports the treatment of mouth and throat infections and the debridement and moistening of mouth lesions and thrush.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Birnbaum Jay E |
Director |
– • – |
2017-11-29 |
4 |
A |
$0.00 |
$0 |
D/D |
13,757 |
23,633 |
|
- |
|
| Barbari Sharon Surrey |
Director |
– • – |
2017-11-29 |
4 |
A |
$0.00 |
$0 |
D/D |
13,944 |
24,782 |
|
- |
|
| Mclaughlin John |
Director |
– • – |
2017-11-29 |
4 |
A |
$0.00 |
$0 |
D/D |
14,317 |
27,778 |
|
- |
|
| Miller Robert E |
Chief Financial Officer |
• – – |
2017-11-29 |
4 |
B |
$5.02 |
$8,991 |
I/I |
1,790 |
14,068 |
1.99 |
- |
|
| Schutz James J |
Chief Executive Officer |
• • – |
2017-11-29 |
4 |
B |
$5.03 |
$2,012 |
D/D |
400 |
15,829 |
2.73 |
- |
|
| Schutz James J |
Chief Executive Officer |
• • – |
2017-11-24 |
4 |
B |
$5.05 |
$1,283 |
D/D |
254 |
15,429 |
2.73 |
- |
|
| Miller Robert E |
Chief Financial Officer |
• – – |
2017-11-21 |
4 |
B |
$5.03 |
$10,065 |
I/I |
2,000 |
12,278 |
1.99 |
- |
|
| Mclaughlin John |
Director |
– • – |
2017-08-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,210 |
13,471 |
|
- |
|
| Harrison Russell Joseph |
Director |
– • – |
2017-08-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,045 |
11,950 |
|
- |
|
| Barbari Sharon Surrey |
Director |
– • – |
2017-08-29 |
4 |
A |
$0.00 |
$0 |
D/D |
880 |
10,838 |
|
- |
|
| Birnbaum Jay E |
Director |
– • – |
2017-08-29 |
4 |
A |
$0.00 |
$0 |
D/D |
715 |
9,876 |
|
- |
|
| Miller Robert E |
Chief Financial Officer |
• – – |
2017-08-10 |
4 |
B |
$5.30 |
$11,999 |
I/I |
2,264 |
10,728 |
1.99 |
- |
|
| Umscheid Marc |
Chief Strategy/Mkt Officer |
• – – |
2017-08-10 |
4 |
B |
$5.31 |
$3,186 |
D/D |
600 |
3,392 |
2.66 |
- |
|
| Schutz James J |
Chief Executive Officer |
• • – |
2017-08-10 |
4 |
B |
$5.46 |
$5,069 |
D/D |
929 |
15,175 |
2.81 |
- |
|
| Northey Robert Allen |
Exe. VP of Research and Dev. |
• – – |
2017-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
3,404 |
8,082 |
|
- |
|
| Umscheid Marc |
Chief Strategy/Mkt Officer |
• – – |
2017-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,042 |
2,792 |
|
- |
|
| Miller Robert E |
Chief Financial Officer |
• – – |
2017-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
4,124 |
20,088 |
|
- |
|
| Schutz James J |
Chief Executive Officer |
• • – |
2017-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,406 |
14,246 |
|
- |
|
| Birnbaum Jay E |
Director |
– • – |
2017-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
612 |
9,161 |
|
- |
|
| Barbari Sharon Surrey |
Director |
– • – |
2017-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
754 |
9,958 |
|
- |
|
| Mclaughlin John |
Director |
– • – |
2017-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
1,036 |
12,261 |
|
- |
|
| Harrison Russell Joseph |
Director |
– • – |
2017-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
895 |
10,905 |
|
- |
|
| Miller Robert E |
Chief Financial Officer |
• – – |
2017-03-09 |
4 |
B |
$6.96 |
$5,268 |
I/I |
750 |
8,464 |
1.99 |
- |
|
| Miller Robert E |
Chief Financial Officer |
• – – |
2017-03-08 |
4 |
B |
$6.81 |
$6,930 |
I/I |
1,000 |
7,714 |
1.99 |
- |
|
| Schutz James J |
Chief Executive Officer |
• • – |
2017-03-03 |
4 |
B |
$6.75 |
$5,421 |
D/D |
800 |
11,840 |
2.81 |
- |
|
74 Records found
|
|
Page 2 of 3 |
|
|
